Navigation Links
POSITIVEID In Businessweek For Bid On U$5.7 Billion BIOWATCH Program
Date:6/26/2012

Delray Beach Florida USA (PRWEB) June 26, 2012

DELRAY BEACH, FL – PositiveID Corporation (OTCBB: PSID) an emerging growth company and developer of sophisticated airborne bio-threat detection systems for America’s homeland defense appeared in Bloomberg Businessweek in an article (http://www.businessweek.com/articles/2012-06-21/the-sky-high-price-of-sniffing-out-anthrax) on the estimated $5.7 billion BioWatch procurement by the U.S. Department of Homeland Security (“DHS”).

PositiveID’s M-BAND, its Microfluidics-based Bioagent Autonomous Networked Detector, was developed under contract for the Department of Homeland Security, and is an early warning system designed to detect the intentional release of aerosolized biological agents. William J. Caragol, Chairman and CEO of PositiveID, said, “We believe we are well positioned to compete for Generation 3 of the BioWatch program and we continue to work toward the expected deployment of our bioaerosol detectors. We are extremely proud of our accomplishments in the development of this system over the last eight years, including, we believe, numerous technology advantages, as we have prepared our M-BAND system for this important program for our homeland defense. As one of only two viable solutions for the BioWatch Generation 3 program, and with the proven technology and flexibility to make it work, we believe we are well positioned to participate in this estimated $5.7 billion program.”

PositiveID’s M-BAND runs autonomously for up to 30 days between service cycles, continuously analyzing air samples, typically in high-traffic areas, for the detection of bacteria, viruses, and toxins with results in as little as three hours. Results from individual M-BAND instruments are reported via a secure wireless network in real time. Designed with a high level of operational flexibility, M-BAND can be remotely set to detect for DNA-based pathogens alone, with or without either RNA-based organisms or toxins, or for all three types of pathogens simultaneously at remotely programmable intervals.

About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America’s homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats, as well as analyze samples in a medical environment.

For more information please email:
info(at)massmedia77(dot)com

Copyright © 2012 All rights reserved.
PR: http://www.MassMedia77.com
Sound Marketing is Smart Business

Safe Harbor Statement

This report includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2010 and beyond could differ materially from the Company’s current expectations.

Forward-looking statements are identified by words such as “anticipates,” “projects,” “expects,” “plans,” “intends,” “believes,” “estimates,” “targets,” and other similar expressions that indicate trends and future events.        

Factors that could cause the Company’s results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company’s products and services, the frequency, magnitude and timing of paper and other raw-material-price changes, general business and economic conditions beyond the Company’s control, timing of the completion and integration of acquisitions, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of the MyC3 initiative and other cost-containment strategies, and the Company’s success in attracting and retaining key personnel. Additional information concerning factors that could cause actual results to differ materially from those projected is contained in the Company’s filing with The Securities and Exchange Commission. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information since these statements may no longer be accurate or timely.

Analysts’ Compensation: Mass Media 77, Inc. who in part or in whole may be responsible for the preparation of this report may receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Institutional Equities and Investment Banking and restricted stock.

Information has been obtained from sources believed to be reliable but Mass Media 77, Inc or its affiliates and/or subsidiaries (collectively Mass Media 77, Inc.) do not warrant its completeness or accuracy. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Additional information may be available upon request.

Read the full story at http://www.prweb.com/releases/2012_PositiveID_In_/06_Businessweek_Mag_/prweb9641115.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
3. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
4. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
5. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
6. Cowen Healthcare Royalty Partners Raises $1 Billion
7. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
8. MarketsandMarkets: Global Biomarkers Market worth $25.79 Billion by 2016
9. RiverVest Venture Partners Sells Four Successful Life Science Companies for More than $1 Billion
10. Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
11. Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):